IG
ALXN

Ithaka Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Ithaka Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-67,756
Closed -$6.6M – 40
2018
Q4 		$6.6M Sell
67,756
-3,971
-6% -$469K 1.21% 29
2018
Q3 		$9.97M Sell
71,727
-6,695
-9% -$840K 1.48% 28
2018
Q2 		$9.74M Sell
78,422
-1,744
-2% -$204K 1.51% 28
2018
Q1 		$8.94M Sell
80,166
-1,182
-1% -$141K 1.5% 28
2017
Q4 		$9.73M Sell
81,348
-1,793
-2% -$218K 1.74% 24
2017
Q3 		$11.7M Sell
83,141
-4,369
-5% -$594K 2.14% 18
2017
Q2 		$10.6M Buy
87,510
+241
+0.3% +$28K 1.93% 20
2017
Q1 		$10.6M Sell
87,269
-6,157
-7% -$794K 2.05% 19
2016
Q4 		$11.4M Sell
93,426
-19,418
-17% -$2.38M 2.25% 19
2016
Q3 		$13.8M Sell
112,844
-18,974
-14% -$2.44M 2.17% 18
2016
Q2 		$15.4M Sell
131,818
-3,357
-2% -$476K 2.23% 17
2016
Q1 		$18.8M Buy
135,175
+34,002
+34% +$4.99M 2.72% 14
2015
Q4 		$19.3M Buy
101,173
+6,713
+7% +$1.17M 2.58% 16
2015
Q3 		$14.8M Buy
94,460
+13,093
+16% +$2.39M 2.27% 20
2015
Q2 		$14.7M Buy
81,367
+19,888
+32% +$3.43M 2.47% 17
2015
Q1 		$10.7M Sell
61,479
-5,751
-9% -$1.04M 1.69% 29
2014
Q4 		$12.4M Sell
67,230
-5,826
-8% -$1.08M 1.95% 26
2014
Q3 		$12.1M Sell
73,056
-3,235
-4% -$531K 1.82% 28
2014
Q2 		$11.9M Buy
76,291
+9,019
+13% +$1.42M 1.73% 27
2014
Q1 		$10.2M Buy
67,272
+9,817
+17% +$1.56M 1.7% 29
2013
Q4 		$7.63M Buy
57,455
+7,366
+15% +$884K 1.44% 32
2013
Q3 		$5.82M Buy
50,089
+2,806
+6% +$308K 1.35% 33
2013
Q2 		$4.36M Buy
+47,283
New +$4.56M 1.28% 35

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ithaka Group's ALXN Position: Q1 2019 in Review

Ithaka Group sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 67,756 shares — an estimated $6.6M sold.

Ithaka Group first reported a position in ALXN in Q2 2013 and held it in 23 quarters. The position peaked at $19.3M in Q4 2015. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Ithaka Group reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Ithaka Group sold 67,756 Alexion Pharmaceuticals shares in Q1 2019, an estimated $6.6M.
  • Ithaka Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Ithaka Group's Alexion Pharmaceuticals position peaked at $19.3M in Q4 2015.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Ithaka Group's 13F filing for Q1 2019, filed 13 May 2019.